FibroGen Inc <FGEN.OQ> expected to post a loss of $2.31 a share - Earnings Preview

• FibroGen Inc FGEN.OQ FGEN.O is expected to show a fall in quarterly revenue when it reports results on August 11 for the period ending June 30 2025

• The San Francisco California-based company is expected to report a 94.8% decrease in revenue to $2.63 million from $50.64 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for FibroGen Inc is for a loss of $2.31 per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for FibroGen Inc is $250.00, about 96.8% above its last closing price of $7.94

This summary was machine generated August 8 at 21:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)